TVTX · Travere Therapeutics, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $55.0179, and the range of prices were between $54.63 and $55.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
78,400 |
| 2026-10-15 | Dube Eric M |
Director |
Convert↑
|
Common Stock
|
200,000 |
| 2026-10-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $52.9672, and the range of prices were between $52.63 and $53.6250. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
128,065 |
| 2026-10-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $54.1997, and the range of prices were between $53.63 and $54.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
37,270 |
| 2026-10-15 | Dube Eric M |
Director |
Convert↑
|
Common Stock
|
43,735 |
| 2026-10-15 | Dube Eric M |
Director |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
One-fourth of the shares subject to the stock option vested and became exercisable on January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |
Employee stock option (right to buy)
|
200,000 |
| 2026-10-15 | Dube Eric M |
Director |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
43,735 |
| 2026-09-17 | Dube Eric M |
Director |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
108,493 |
| 2026-09-17 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
6,802 |
| 2026-09-17 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
101,691 |
| 2026-09-17 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
Employee stock option (right to buy)
|
8,282 |
| 2026-09-17 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
|
Common Stock
|
8,282 |
| 2026-09-17 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
8,282 |
| 2026-09-17 | Dube Eric M |
Director |
Convert↑
|
Common Stock
|
108,493 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
93,604 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
79,113 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
55,000 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
|
Common Stock
|
100,000 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
350 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↑
|
Common Stock
|
55,000 |
| 2026-09-16 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
99,716 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
|
Common Stock
|
55,000 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
57,500 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
17,717 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
55,000 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↑
|
Common Stock
|
350 |
| 2026-09-16 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
96,125 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↑
|
Common Stock
|
57,500 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
|
Common Stock
|
17,717 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
65,104 |
| 2026-09-16 | Dube Eric M |
Director |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
195,841 |
| 2026-09-16 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
100,000 |
| 2026-09-16 | ROTE WILLIAM E. |
Chief Research Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
47,746 |
| 2026-09-16 | Dube Eric M |
Director |
Convert↑
|
Common Stock
|
195,841 |
| 2026-09-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
3,102 |
| 2026-09-15 | Inrig Jula |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
Employee stock option (right to buy)
|
32,395 |
| 2026-09-15 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
Common Stock
|
39,283 |
| 2026-09-15 | Cline Christopher R. |
CHIEF FINANCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
27,473 |
| 2026-09-15 | ROTE WILLIAM E. |
Chief Research Officer |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
39,000 |
| 2026-09-15 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Convert↑
|
Common Stock
|
1,381 |
| 2026-09-15 | Inrig Jula |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
17,284 |
| 2026-09-15 | REED ELIZABETH E |
Chief Legal Officer and GC |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
1,400 |
| 2026-09-15 | Calvin Sandra |
SVP, CHIEF ACCOUNTING OFFICER |
Convert↑
|
Common Stock
|
2,500 |
| 2026-09-15 | Inrig Jula |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
32,395 |
| 2026-09-15 | Dube Eric M |
Director |
Convert↓
Filing footnotes — Employee stock option (right to buy) (Direct)
The stock option is fully vested and exercisable. |
Employee stock option (right to buy)
|
95,666 |
| 2026-09-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
63,498 |
| 2026-09-15 | Dube Eric M |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
28,796 |
| 2026-09-15 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
1,400 |
| 2026-09-15 | Heerma Peter |
CHIEF COMMERCIAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
1,431 |
| 2026-09-15 | Inrig Jula |
CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
Common Stock
|
25,390 |